Dendritic cells fused with allogeneic hepatocellular carcinoma cell line compared with fused autologous tumor cells as hepatocellular carcinoma vaccines.
Jun 2010 - Hepatol. Res.; 40(5):1386-6346 [PMID:20374301]
[Yang JY] [Cao DY] [Ma LY] [Liu WC]

Immunotherapy of hepatocellular carcinoma.
Jun 2010 - Expert Rev Gastroenterol Hepatol; 4(3):1747-4132 [PMID:20528121]
[Korangy F] [Höchst B] [Manns MP] [Greten TF]

Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma.
Apr 2010 - J. Gastroenterol.; 45(4):1435-5922 [PMID:19936602]
[Hiroishi K] [Eguchi J] [Baba T] [Shimazaki T] [Ishii S] [Hiraide A] [Sakaki M] [Doi H] [Uozumi S] [Omori R] [Matsumura T] [Yanagawa T] [Ito T] [Imawari M]

Dendritic Cells-based Vaccine and Immune Monitoring for Hepatocellular Carcinoma.
Mar 2010 - Korean J. Physiol. Pharmacol.; 14(1):1226-4512 [PMID:20221274]
[Lee DH]

Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma.
Mar 2010 - :1432-1335 [PMID:20221638]
[Shen X] [Li N] [Li H] [Zhang T] [Wang F] [Li Q]

Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma.
Oct 2009 - Mol. Ther.:1525-0024 [PMID:19809404]
[Altomonte J] [Marozin S] [Schmid RM] [Ebert O]

Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Aug 2009 - Cell. Immunol.; 259(1):1090-2163 [PMID:19545862]
[Cao DY] [Yang JY] [Yue SQ] [Tao KS] [Song ZS] [Wang DS] [Yang YL] [Dou KF]

A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
Jan 2009 - Hepatology; 49(1):1527-3350 [PMID:18980227]
[Palmer DH] [Midgley RS] [Mirza N] [Torr EE] [Ahmed F] [Steele JC] [Steven NM] [Kerr DJ] [Young LS] [Adams DH]

The anti-tumor effect of human monocyte-derived dendritic cells loaded with HSV-TK/GCV induced dying cells.
Dec 2008 - Cell. Immunol.; 254(2):1090-2163 [PMID:18834973]
[Xing W] [Wu S] [Yuan X] [Chen Q] [Shen X] [He F] [Bian J] [Lei P] [Zhu H] [Wang S] [Shen G]

In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.
Oct 2008 - J Transl Med; 6:1479-5876 [PMID:18793383]
[Koido S] [Homma S] [Hara E] [Mitsunaga M] [Namiki Y] [Takahara A] [Nagasaki E] [Komita H] [Sagawa Y] [Ohkusa T] [Fujise K] [Gong J] [Tajiri H]

CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Jul 2008 - Hepatology; 48(1):1527-3350 [PMID:18537185]
[Gonzalez-Carmona MA] [Lukacs-Kornek V] [Timmerman A] [Shabani S] [Kornek M] [Vogt A] [Yildiz Y] [Sievers E] [Schmidt-Wolf IG] [Caselmann WH] [Sauerbruch T] [Schmitz V]

Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
May 2008 - Hepatogastroenterology; 55(81):0172-6390 [PMID:18507097]
[Yin XY] [Wang L] [Lu MD] [Li BJ] [Huang JF]

Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.
Oct 2007 - Cancer Immunol. Immunother.; 56(12):0340-7004 [PMID:17522860]
[Butterfield LH] [Ribas A] [Potter DM] [Economou JS]

alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Apr 2007 - Hum. Immunol.; 68(5):0198-8859 [PMID:17462500]
[Cao DY] [Yang JY] [Dou KF] [Ma LY] [Teng ZH]

AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.
Apr 2007 - J. Immunother.; 30(4):1524-9557 [PMID:17457217]
[Evdokimova VN] [Liu Y] [Potter DM] [Butterfield LH]